Baby's hand holding its mother's finger

Newsroom

Latest News

News

SERA REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

Sera announced financial results for the second quarter of 2024 ended June 30, 2024.
News

Sera Announces Conference Call and Webcast of Second Quarter Fiscal Year 2024 Financial Results on August 7, 2024

Sera announced that it will report second quarter fiscal year 2024 financial results on Wednesday, August 7, 2024, after the close of the market.
News

Sera PreTRM® Test Prevention Strategy Demonstrates 18% Reduction in Severe Neonatal Morbidity and Mortality in Newly Published AVERT Trial

Sera Announces Publication of Positive AVERT PRETERM TRIAL Results in the International Peer-Reviewed Journal, Diagnostics
News

SERA ADDED TO RUSSELL 2000 AND 3000 INDEXES FOLLOWING CONCLUSION OF 2024 INDEXES ANNUAL RECONSTITUTION

Sera announced that as a result of the annual Rusell Reconstitution being finalized on June 28, 2024, the Company has been added to the Russell Small-Cap 2000 and Russell 3000 indexes
News

SERA EXPECTED TO BE ADDED TO RUSSELL 2000 AND 3000 INDEXES

Sera announced that it has been added to the preliminary list of the Russell Small-Cap 2000 and Russell 3000 indexes
News

SERA REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

Sera announced financial results for the first quarter of 2024 ended March 31, 2024.
News

SERA REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS

Sera announced financial results for the fourth quarter and full year ended December 31, 2023.
News

Sera Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2023 Financial Results on March 20, 2024

Sera announced that it will report fourth quarter and full year 2023 financial results on Wednesday, March 20
News

Sera To Present at TD Cowen 44th Annual Healthcare Conference

Sera announced that the company will present at the TD Cowen 44th Annual Healthcare Conference on Monday, March 4, 2024 at 2:50 p.m. ET. 
News

SERA ANNOUNCES PRIMARY ENDPOINT CRITERIA MET

Sera today announced that the Data Safety Monitoring Board (DSMB) overseeing its pivotal PRIME study recommended stopping enrollment due to efficacy

Stay in Touch